Adjunctive esketamine in propofol-based sedation for gastrointestinal endoscopy: a systematic review and meta-analysis of randomized trials
Authors:
Open Access
- 25 November 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1662057
Abstract
Background: While propofol is widely used for gastrointestinal endoscopic sedation, its cardiovascular and respiratory side effects and lack of analgesia can compromise safety and comfort. Esketamine provides both sedation and analgesia with minimal hemodynamic or respiratory impact. Combining esketamine with propofol may miti-gate propofol’s adverse effects while enhancing sedation quality. However, the com-bination’s overall safety and efficacy remain inconclusive. Methods: This systematic review and meta-analysis compared propofol-based sedation with versus without intravenous esketamine in gastrointestinal endoscopy, synthesizing evidence from randomized controlled trials. The primary outcome was the incidence of hypotension. Secondary outcomes included intraoperative adverse respiratory events, propofol consumption, involuntary movement, hypertension, arrhythmias, PONV recovery times, and dizziness. Results: Eighteen trials were included in the analysis. Additional esketamine significantly reduced the incidence of hypotension (risk ratio [RR]: 0.32; 95% confidence interval [CI]: 0.24 to 0.43; P < 0.01; I 2 = 44.4%; moderate quality). The addition of esketamine to propofol can reduce the incidence of adverse respiratory events (RR: 0.57, 95% CI: 0.38 to 0.86; P < 0.01; I 2 = 67.8%; moderate quality). Esketamine added to propofol decreased involuntary movement (RR: 0.61, 95% CI: 0.42 to 0.92; P = 0.02; I 2 = 77.2%; low quality) and reduced the propofol consumption (mean difference [MD]: −0.94, 95% CI: −1.53 to −0.35 mg/kg; P < 0.01; I 2 = 96.2%; low quality). No significant differences were found for hypertension, arrhythmias, PONV, recovery time or dizziness. Conclusion: Supplementing propofol-based sedation with esketamine reduced the risk of hypotension and adverse respiratory events, without increasing cardiovascular complications, or extending recovery-time. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD420251030940.Keywords
This publication has 68 references indexed in Scilit:
- Interrupted versus uninterrupted anticoagulation for cardiac rhythm management device insertionCochrane Database of Systematic Reviews, 2025
- National survey on sedation for gastrointestinal endoscopy in 2758 Chinese hospitalsBritish Journal of Anaesthesia, 2021
- Adverse Effects of Esketamine for the Treatment of Major Depression Disorder: Findings from Randomized Controlled TrialsPsychiatric Quarterly, 2021
- Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of InterventionsCochrane Database of Systematic Reviews, 2019
- Esketamine counters opioid-induced respiratory depressionBritish Journal of Anaesthesia, 2018
- Midazolam and Other Benzodiazepines2008
- Propofol and Propofol–Ketamine in Pediatric Patients Undergoing Cardiac CatheterizationPediatric Cardiology, 2005
- Aufwachzeit nach (S)-Ketamin- oder Ketamin-RazematDer Anaesthesist, 1998
- Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in HumansArchives of General Psychiatry, 1994
- Haemodynamic effects of ketamine and thiopentone during anaesthetic induction for Caesarean sectionCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 1985